Memorandum of Understanding
between
INTERNATIONAL UNION OF BASIC AND CLINICAL PHARMACOLOGY
and
KAROLINSKA INSTITUTET, SWEDEN

International Union of Basic and Clinical Pharmacology (IUPHAR), and Karolinska Institutet, a medical university, Sweden (hereinafter, jointly or individually, referred to as “Parties” or “Party” to this Memorandum) believe that:

1. Mutual benefit can be derived from academic exchange and cooperation in education and research within the area of Pharmacology and Clinical Pharmacology;

2. The Parties regard the following areas of cooperation as described separately in a implementation agreement as desirable and feasible within the limits of available resources and interests:
   (i) Co-operation in specified areas of mutual interest; such as Academic Drug Discovery and Development, Drug Metabolism, Critical Drug Evaluation and Drug Information
   (ii) Collaborative research and possible exchange of academic papers;
   (iii) Joint applications to raise funds for collaborative activities
   (iv) Joint academic and scientific activities, such as courses, conferences, seminars, workshops or lectures and open provision to scientific information;
   (v) Exchange of scientific materials, publications and other information

3. The terms of specific areas of cooperation shall be further considered and agreed upon in writing by the Parties prior to the initiation of any particular programme or activity.

4. This Memorandum of Understanding (MoU) describes in general terms the basis upon which the Parties intend to collaborate. All activities undertaken pursuant to the Memorandum are subject to the approval of the Parties themselves. This MoU does not affect the ability of the Parties to enter into other agreements or arrangements. Any specific programme or activity will be subject to mutual consent, availability of funds and approval of both Parties.

5. Each Party shall ensure that its activities under cooperation fully comply with all recognised laws, regulations, guidelines and recommendations in relevant fields, that are in force during the term of this agreement, including but not limited to:
   (i) Any UNESCO Declaration on Ethics Issues, for instance the Universal Declaration on the Human Genome and Human Rights, the International Declaration on Human Genetic Data and the Universal Declaration on Bioethics and Human Rights;
   (ii) Generally accepted principles of academic freedom and in particular the Recommendation concerning the Status of Higher Education Teaching Personnel, adopted by the UNESCO General Conference in 1997;
(iii) All applicable local, government laws and regulations and guidelines governing health and safety, data protection, and where relevant, the use of human or animal subjects, good laboratory practice and good clinical practice; and

(iv) Any World Medical Association policy included in the Handbook of WMA Policy, for instance The Helsinki Declaration on Ethical Principles for Medical Research involving Human Subjects, International Code of Medical Ethics, Declaration on Ethical Considerations regarding Health Databases and Statement on Animal Use in Biomedical Research.

The Parties acknowledge that in all research activities under the collaboration they shall secure all necessary approvals from the relevant research ethics committees before undertaking any part of a research project requiring ethics committee approval. Each Party shall also obtain properly signed consent and acknowledgement forms from any human subjects or their legal guardians to be involved in the project;

The Parties will cooperate for the purpose of ensuring that each of them complies with ethical obligations and will therefore share information relating to ethical approvals obtained in a transparent manner.

The Parties agree to ensure that all teaching and research personnel engaged in the collaboration under the current MoU shall be entitled to full academic freedom as referred to in (ii) above.

6. The Parties agree that this MoU does not give rise to any legal relationship, rights, duties or consequences, except the obligation in clause 5 above. Specifically neither Party acquires any license under intellectual property rights of the other Party.

7. Neither Party shall use the trade/official-marks or trade/official names, of the other or of any of its affiliates, directly or indirectly, in connection with any product, promotion, advertising, press releases, service or publication without the prior written consent of the other Party.

8. This MoU will be effective when signed by both Parties. The term of duration of this MoU shall be of five (5) years and may be extended for additional five-year periods by written consent of the Parties. Either Party may terminate this agreement by giving the other Party at least six (6) months written notice.

SIGNED for and on behalf of:

IUPHAR by:

[Signature]
Prof. Ingolf Cascorbi
President
International Union of Basic and Clinical Pharmacology (IUPHAR)

Date: 02.04.2015

Karolinska Institutet by:

[Signature]
Prof. Ole Petter Ottersen
President
Karolinska Institutet

Date: 240119
Contact persons and contact details:

**International Union of Basic and Clinical Pharmacology**

**Scientific;**

Dr. Michael Spedding  
Secretary General  
Spedding Research Solutions SAS,  
6 Rue Ampère  
Le Vesinet, 78110  
France.  
Tel: +33637059188  
E-mail: Michael@speddingresearchsolutions.fr  
www.iuphar.org

**Administrative;**

Kristen Kovach  
Executive Officer  
5034A Thoroughbred Lane  
Brentwood  
TN 37027  
USA  
Tel: +1-615-324-2365  
E-mail: admin@iuphar  
www.iuphar.org

**Karolinska Institutet**

**Scientific;**

Prof Lars L Gustafsson/Prof Marja-Liisa Dahl  
Karolinska Institutet  
Department of Laboratory Medicine  
Division of Clinical pharmacology  
SE-141 86 Stockholm  
Sweden  
Tel: +46 (0) 8-524 80 000 (switchboard)  
E-mail: Lars.L.Gustafsson@ki.se and Marja-liisa.Dahl@ki.se  
www.ki.se

**Administrative;**

Johanna Ackemar  
International Coordinator  
Karolinska Institutet  
Faculty Office and External Relations  
SE-171 77 Stockholm  
Sweden  
Tel: +46 (0) 8-524 80 000 (switchboard)  
E-mail: johanna.ackemar@ki.se  
www.ki.se